People in the United States have had access to GlaxoSmithKline’s long-acting HIV treatment for nearly a year. Now the game-changing therapy will be available to people in England and Wales.
In addition to the once-monthly, complete long-acting regimen, Canada has also approved Vocabria (cabotegravir) oral tablets, to be used for short time periods in conjunction with Cabenuva in the indication of HIV-1 infection.
FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets
HIV patients will have to wait a while longer for a long-acting viral suppression regimen as the FDA has rejected ViiV Healthcare’s NDA for the monthly injection of cabotegravir and rilpivirine.
Johnson & Johnson’s sponsored AIDS film didn’t win at the Brand Film Festival in New York last week, but it had already won a different prize just a few days earlier.
Over time, the approved therapeutic uses of prescription medicines registered on the Australian Register of Therapeutic Goods (ARTG) can change.
GlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it's already bolstering its trial program to see just how convenient it can make a two-drug regimen.
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
GSK and Gilead Sciences were among the headliners at the first major HIV confab of the year, the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, and they kicked off the show with data on two drug regimens that analysts predict will be dueling blockbusters.
Gilead Sciences ($GILD) won FDA approval for another combination treatment for HIV, building around a cornerstone antiviral therapy as it works to expand its dominance in the field.